Citation

Noureldin M, Van T, Cohen-Mekelburg S, Scott FI, Higgins PDR, Stidham RW, Hou J, Waljee AK, Berinstein JA. Am. J. Gastroenterol. 2024; ePub(ePub): ePub.

Copyright

(Copyright © 2024, Nature Publishing Group)

DOI

10.14309/ajg.0000000000002834

PMID

38767951

Abstract

INTRODUCTION: Cannabis may provide inflammatory bowel disease (IBD) patients with an alternative to opioids for pain.

METHODS: We conducted a difference-in-difference analysis using MarketScan. Changes over time in rates of opioid prescribing were compared in states with legalized cannabis to those without.

RESULTS: We identified 6,240 patients with IBD in states with legalized cannabis and 79,272 patients with IBD in states without legalized cannabis. The rate of opioid prescribing decreased over time in both groups and were not significantly different (attributed differential = 0.34, confidence interval -13.02 to 13.70, P = 0.96).

DISCUSSION: Opioid prescribing decreased from 2009 to 2016 among patients with IBD in both states with legalized and state without legalized cannabis, similar to what has been observed nationally across a variety of diseases. Cannabis legalization was not associated with a lower rate of opioid prescribing for patients with IBD.

Language: en